CRBP stock touches 52-week low at $9.26 amid market challenges
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $9.26, as investors respond to a series of market headwinds. According to InvestingPro data, the stock's ...
Hosted on MSN19h
AdAlta boosts leadership in Q2 FY25 to support growth strategy
FY25 saw AdAlta focus on increasing its corporate muscle, with two new board members and additional advisors engaged. ...
pulmonaryfibrosisnews3d
Study uncovers why PF after severe COVID-19 doesn’t progress
An imbalance in gene activity in two types of immune cells explains why lung fibrosis after a severe COVID-19 infection doesn ...
89bio price target raised to $38 from $25 at UBS, says shares ‘undervalued’
UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...
Piper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)
Piper Sandler analyst Biren Amin maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel ...
Le Lézard5d
The FDA Grants Vicore's Buloxibutid Fast Track Designation for Idiopathic Pulmonary Fibrosis
STOCKHOLM, SE / ACCESS Newswire / January 29, 2025 / Vicore Pharma Holding (STO:VICO)Stockholm, January 29, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of ...